» Articles » PMID: 38351345

Crosstalk Between Endothelial Progenitor Cells and HCC Through Periostin/CCL2/CD36 Supports Formation of the Pro-metastatic Microenvironment in HCC

Abstract

Metastasis causes most cancer-related deaths, and the role and mechanism of periostin (POSTN) in the metastasis of hepatocellular carcinoma (HCC) remain undiscovered. In this study, DEN and HTVi HCC models were performed in hepatic-specific Postn ablation and Postn knock-in mouse to reveal the role of POSTN in HCC metastasis. Furthermore, POSTN was positively correlated with circulating EPCs level and promoted EPC mobilization and tumour infiltration. POSTN also mediated the crosstalk between HCC and EPCs, which promoted metastasis ability and upregulated CD36 expression in HCC through indirect crosstalk. Chemokine arrays further revealed that hepatic-derived POSTN induced elevated CCL2 expression and secretion in EPCs, and CCL2 promoted prometastatic traits in HCC. Mechanistic studies showed that POSTN upregulated CCL2 expression in EPCs via the αvβ3/ILK/NF-κB pathway. CCL2 further induced CD36 expression via the CCR2/STAT3 pathway by directly binding to the promoter region of CD36. Finally, CD36 was verified to have a prometastatic role in vitro and to be correlated with POSTN expression, metastasis and recurrence in HCC in clinical samples. Our findings revealed that crosstalk between HCC and EPCs is mediated by periostin/CCL2/CD36 signalling which promotes HCC metastasis and emphasizes a potential therapeutic strategy for preventing HCC metastasis.

Citing Articles

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma.

Li J, Zhang G, Li G, Zhang J, Yang Z, Yang L Discov Oncol. 2025; 16(1):121.

PMID: 39909958 PMC: 11799483. DOI: 10.1007/s12672-025-01897-6.


Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.

Chan H, Kuo D, Shueng P, Chuang H Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770505 PMC: 11676442. DOI: 10.3390/ph17121663.


Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity.

Cioce M, Arbitrio M, Polera N, Altomare E, Rizzuto A, De Marco C Cancer Drug Resist. 2024; 7:45.

PMID: 39624081 PMC: 11609178. DOI: 10.20517/cdr.2024.131.


CCL2 Predicts Survival in Patients with Inoperable Hepatocellular Carcinoma Undergoing Selective Internal Radiotherapy.

Haag F, Gylstorff S, Bujok J, Pech M, Relja B Cancers (Basel). 2024; 16(16).

PMID: 39199602 PMC: 11352291. DOI: 10.3390/cancers16162832.


Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways.

Khan F, Elsori D, Verma M, Pandey S, Rab S, Siddiqui S Front Cell Dev Biol. 2024; 12:1399065.

PMID: 38933330 PMC: 11199418. DOI: 10.3389/fcell.2024.1399065.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

3.
Llovet J, De Baere T, Kulik L, Haber P, Greten T, Meyer T . Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(5):293-313. DOI: 10.1038/s41575-020-00395-0. View

4.
Wasik A, Ratajczak-Wielgomas K, Badzinski A, Dziegiel P, Podhorska-Okolow M . The Role of Periostin in Angiogenesis and Lymphangiogenesis in Tumors. Cancers (Basel). 2022; 14(17). PMC: 9454705. DOI: 10.3390/cancers14174225. View

5.
Chen G, Wang Y, Zhao X, Xie X, Zhao J, Deng T . A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation. J Exp Clin Cancer Res. 2021; 40(1):218. PMC: 8243733. DOI: 10.1186/s13046-021-02011-8. View